{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T17:05:07Z","timestamp":1779555907042,"version":"3.53.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,23]]},"DOI":"10.7759\/cureus.109507","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T16:32:51Z","timestamp":1779553971000},"source":"Crossref","is-referenced-by-count":0,"title":["Development of the Gutti Score: A Universal Clinical Assessment Framework for Patients Receiving Gabapentinoids, Opioids, Benzodiazepines, and Other Central Nervous System Depressants"],"prefix":"10.7759","author":[{"given":"Sai","family":"Gutti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah","family":"Riyadh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study","volume":"14","author":"Gomes T","year":"2017","unstructured":"Gomes T, Juurlink DN, Antoniou T, et al.. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017, 14:e1002396. 10.1371\/journal.pmed.1002396","journal-title":"PLoS Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith RV","year":"2016","unstructured":"Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016, 111:1160-74. 10.1111\/add.13324","journal-title":"Addiction"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S144963","article-title":"Risk of respiratory depression with opioids and concomitant gabapentinoids","volume":"10","author":"Savelloni J","year":"2017","unstructured":"Savelloni J, Gunter H, Lee KC, et al.. Risk of respiratory depression with opioids and concomitant gabapentinoids. J Pain Res. 2017, 10:2635-41. 10.2147\/JPR.S144963","journal-title":"J Pain Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002965","article-title":"Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records","volume":"16","author":"Macleod J","year":"2019","unstructured":"Macleod J, Steer C, Tilling K, et al.. Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records. PLoS Med. 2019, 16:e1002965. 10.1371\/journal.pmed.1002965","journal-title":"PLoS Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-020-00189-x","article-title":"Gabapentinoid benefit and risk stratification: mechanisms over myth","volume":"9","author":"McAnally H","year":"2020","unstructured":"McAnally H, Bonnet U, Kaye AD. Gabapentinoid benefit and risk stratification: mechanisms over myth. Pain Ther. 2020, 9:441-52. 10.1007\/s40122-020-00189-x","journal-title":"Pain Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain--United States, 2016","volume":"315","author":"Dowell D","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain--United States, 2016. JAMA. 2016, 315:1624-45. 10.1001\/jama.2016.1464","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S130942","article-title":"Rational dosing of gabapentin and pregabalin in chronic kidney disease","volume":"10","author":"Raouf M","year":"2017","unstructured":"Raouf M, Atkinson TJ, Crumb MW, Fudin J. Rational dosing of gabapentin and pregabalin in chronic kidney disease. J Pain Res. 2017, 10:275-8. 10.2147\/JPR.S130942","journal-title":"J Pain Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01967-2015","article-title":"Incident opioid drug use and adverse respiratory outcomes among older adults with COPD","volume":"48","author":"Vozoris NT","year":"2016","unstructured":"Vozoris NT, Wang X, Fischer HD, et al.. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2016, 48:683-93. 10.1183\/13993003.01967-2015","journal-title":"Eur Respir J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00985-6","article-title":"Current evidence on abuse and misuse of gabapentinoids","volume":"43","author":"H\u00e4gg S","year":"2020","unstructured":"H\u00e4gg S, J\u00f6nsson AK, Ahlner J. Current evidence on abuse and misuse of gabapentinoids. Drug Saf. 2020, 43:1235-54. 10.1007\/s40264-020-00985-6","journal-title":"Drug Saf"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.01.018","article-title":"Prevalence of gabapentin in drug overdose postmortem toxicology testing results","volume":"186","author":"Slavova S","year":"2018","unstructured":"Slavova S, Miller A, Bunn TL, et al.. Prevalence of gabapentin in drug overdose postmortem toxicology testing results. Drug Alcohol Depend. 2018, 186:80-5. 10.1016\/j.drugalcdep.2018.01.018","journal-title":"Drug Alcohol Depend"},{"key":"ref11","unstructured":"Joint Clinical Practice Guideline on Benzodiazepine Tapering. Benzodiazepine dose equivalents. (2025). Accessed: May 17, 2026: https:\/\/downloads.asam.org\/sitefinity-production-blobs\/docs\/default-source\/guidelines\/benzodiazepine-tapering-2025\/be...."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain - United States, 2022","volume":"71","author":"Dowell D","year":"2022","unstructured":"Dowell D, Ragan KR, Jones CM, et al.. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep. 2022, 71:1-95. 10.15585\/mmwr.rr7103a1","journal-title":"MMWR Recomm Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2014.11.007","article-title":"Assessing risk for drug overdose in a national cohort: role for both daily and total opioid dose?","volume":"16","author":"Liang Y","year":"2015","unstructured":"Liang Y, Turner BJ. Assessing risk for drug overdose in a national cohort: role for both daily and total opioid dose?. J Pain. 2015, 16:318-25. 10.1016\/j.jpain.2014.11.007","journal-title":"J Pain"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193134","article-title":"Gabapentin dose and the 30-day risk of altered mental status in older adults: a retrospective population-based study","volume":"13","author":"Fleet JL","year":"2018","unstructured":"Fleet JL, Dixon SN, Kuwornu PJ, et al.. Gabapentin dose and the 30-day risk of altered mental status in older adults: a retrospective population-based study. PLoS One. 2018, 13:e0193134. 10.1371\/journal.pone.0193134","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11126-016-9421-7","article-title":"Abuse of gabapentin is associated with opioid addiction","volume":"87","author":"Bastiaens L","year":"2016","unstructured":"Bastiaens L, Galus J, Mazur C. Abuse of gabapentin is associated with opioid addiction. Psychiatr Q. 2016, 87:763-7. 10.1007\/s11126-016-9421-7","journal-title":"Psychiatr Q"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.09.030","article-title":"Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity","volume":"123","author":"Zand L","year":"2010","unstructured":"Zand L, McKian KP, Qian Q. Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. Am J Med. 2010, 123:367-73. 10.1016\/j.amjmed.2009.09.030","journal-title":"Am J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000000672","article-title":"Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations","volume":"120","author":"Correa D","year":"2015","unstructured":"Correa D, Farney RJ, Chung F, et al.. Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations. Anesth Analg. 2015, 120:1273-85. 10.1213\/ANE.0000000000000672","journal-title":"Anesth Analg"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12495","article-title":"Gabapentin acutely increases the apnea-hypopnea index in older men: data from a randomized, double-blind, placebo-controlled study","volume":"26","author":"Piovezan RD","year":"2017","unstructured":"Piovezan RD, Kase C, Moizinho R, et al.. Gabapentin acutely increases the apnea-hypopnea index in older men: data from a randomized, double-blind, placebo-controlled study. J Sleep Res. 2017, 26:166-70. 10.1111\/jsr.12495","journal-title":"J Sleep Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2015.055","article-title":"Management of benzodiazepine misuse and dependence","volume":"38","author":"Brett J","year":"2015","unstructured":"Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015, 38:152-5. 10.18773\/austprescr.2015.055","journal-title":"Aust Prescr"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2009.00796.x","article-title":"Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy","volume":"11","author":"Toth C","year":"2010","unstructured":"Toth C. Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med. 2010, 11:456-65. 10.1111\/j.1526-4637.2009.00796.x","journal-title":"Pain Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/481302-development-of-the-gutti-score-a-universal-clinical-assessment-framework-for-patients-receiving-gabapentinoids-opioids-benzodiazepines-and-other-central-nervous-system-depressants","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T16:32:52Z","timestamp":1779553972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/481302-development-of-the-gutti-score-a-universal-clinical-assessment-framework-for-patients-receiving-gabapentinoids-opioids-benzodiazepines-and-other-central-nervous-system-depressants"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.109507","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,23]]}}}